Cas No.: | 1614245-70-3 |
Chemical Name: | PF-06372865 |
Synonyms: | Darigabat;7-Ethyl-4-(4'-(ethylsulfonyl)-6-fluoro-2'-methoxybiphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine;7-ethyl-4-[3-(4-ethylsulfonyl-2-methoxyphenyl)-4-fluorophenyl]imidazo[4,5-c]pyridazine;Darigabat [INN];7-Ethyl-4-[4'-(ethylsulfonyl)-6-fluoro-2'-methoxybiphenyl-3-yl]-7H-imidazo[4,5-c]pyridazine;O9BP19HZ3Q;GTPL9798;BDBM144227;TQ0078;example 4 [WO2014091368];PF06372865;US8952008, 4;7-Ethyl-4-(4'-(ethylsulf;PF-06372865 |
SMILES: | S(CC)(C1C=CC(=C(C=1)OC)C1C(=CC=C(C=1)C1C=NN=C2C=1N=CN2CC)F)(=O)=O |
Formula: | C22H21FN4O3S |
M.Wt: | 440.490546941757 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | PF-06372865 is a novel potent, α2/3 functionally selective GABAA receptor positive allosteric modulator; exhibits functional selectivity for receptors containing α2/3/5 subunits, with significant positive allosteric modulation (90-140%) but negligible activity (<20%) at GABAA receptors containing α1 subunits; demonstrates a robust increase in saccadic peak velocity, increases in beta frequency qEEG and a slight saturating increase in body sway in clinical trials.EpilepsyPhase 1 Clinical |